Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Myofibroblasts have an impact on expression, dimerization and signaling of different ErbB receptors in OSCC cells.

Büttner R, Berndt A, Valkova C, Richter P, Korn A, Kosan C, Liebmann C.

J Recept Signal Transduct Res. 2017 Feb;37(1):25-37. doi: 10.3109/10799893.2016.1155066. Epub 2016 Apr 6.

PMID:
27051967
2.

Effects of activated fibroblasts on phenotype modulation, EGFR signalling and cell cycle regulation in OSCC cells.

Berndt A, Büttner R, Gühne S, Gleinig A, Richter P, Chen Y, Franz M, Liebmann C.

Exp Cell Res. 2014 Apr 1;322(2):402-14. doi: 10.1016/j.yexcr.2013.12.024. Epub 2014 Jan 3.

PMID:
24394543
3.

A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer.

Stauber RH, Knauer SK, Habtemichael N, Bier C, Unruhe B, Weisheit S, Spange S, Nonnenmacher F, Fetz V, Ginter T, Reichardt S, Liebmann C, Schneider G, Krämer OH.

Oncotarget. 2012 Jan;3(1):31-43.

4.

Visual field progression outcomes in glaucoma subtypes.

De Moraes CG, Liebmann JM, Liebmann CA, Susanna R Jr, Tello C, Ritch R.

Acta Ophthalmol. 2013 May;91(3):288-93. doi: 10.1111/j.1755-3768.2011.02260.x. Epub 2011 Oct 5.

5.

Allosteric modulation by protein kinase Cε leads to modified responses of EGF receptor towards tyrosine kinase inhibitors.

Weisheit S, Liebmann C.

Cell Signal. 2012 Feb;24(2):422-34. doi: 10.1016/j.cellsig.2011.09.010. Epub 2011 Sep 22.

PMID:
21964064
6.

Examination of the performance of different pointwise linear regression progression criteria to detect glaucomatous visual field change.

De Moraes CG, Liebmann CA, Susanna R Jr, Ritch R, Liebmann JM.

Clin Exp Ophthalmol. 2012 May-Jun;40(4):e190-6. doi: 10.1111/j.1442-9071.2011.02680.x. Epub 2011 Nov 4.

PMID:
21902781
7.

The region of largest β-zone parapapillary atrophy area predicts the location of most rapid visual field progression.

Teng CC, De Moraes CG, Prata TS, Liebmann CA, Tello C, Ritch R, Liebmann JM.

Ophthalmology. 2011 Dec;118(12):2409-13. doi: 10.1016/j.ophtha.2011.06.014. Epub 2011 Sep 1.

PMID:
21885127
8.

PKCε acts as negative allosteric modulator of EGF receptor signalling.

Weisheit S, Schäfer C, Mertens C, Berndt A, Liebmann C.

Cell Signal. 2011 Feb;23(2):436-48. doi: 10.1016/j.cellsig.2010.10.018. Epub 2010 Oct 18.

PMID:
20965248
9.

Activation by tyrosine phosphorylation as a prerequisite for protein kinase Cζ to mediate epidermal growth factor receptor signaling to ERK.

Valkova C, Mertens C, Weisheit S, Imhof D, Liebmann C.

Mol Cancer Res. 2010 May;8(5):783-97. doi: 10.1158/1541-7786.MCR-09-0164. Epub 2010 Apr 20.

10.

EGF receptor activation by GPCRs: an universal pathway reveals different versions.

Liebmann C.

Mol Cell Endocrinol. 2011 Jan 15;331(2):222-31. doi: 10.1016/j.mce.2010.04.008. Epub 2010 Apr 14. Review.

PMID:
20398727
11.

Spatially consistent, localized visual field loss before and after disc hemorrhage.

De Moraes CG, Prata TS, Liebmann CA, Tello C, Ritch R, Liebmann JM.

Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4727-33. doi: 10.1167/iovs.09-3446. Epub 2009 May 20.

PMID:
19458330
12.

Protein kinase Cepsilon may act as EGF-inducible scaffold protein for phospholipase Cgamma1.

Valkova C, Maerz S, Imhof D, Liebmann C.

Cell Signal. 2007 Sep;19(9):1830-43. Epub 2007 Apr 19.

PMID:
17561374
13.

Ligand-independent and EGF receptor-supported transactivation: lessons from beta2-adrenergic receptor signalling.

Drube S, Stirnweiss J, Valkova C, Liebmann C.

Cell Signal. 2006 Oct;18(10):1633-46. Epub 2006 Feb 21.

PMID:
16495036
14.

Muscarinic M2 receptors mediate transactivation of EGF receptor through Fyn kinase and without matrix metalloproteases.

Stirnweiss J, Valkova C, Ziesché E, Drube S, Liebmann C.

Cell Signal. 2006 Aug;18(8):1338-49. Epub 2005 Dec 7.

PMID:
16337776
15.

Activated EGF receptor may balance ERK-inhibitory network signalling pathways.

Hanke S, Valkova C, Stirnweiss J, Drube S, Liebmann C.

Cell Signal. 2006 Jul;18(7):1031-40. Epub 2005 Oct 12.

PMID:
16226010
17.

Tyr-c[D-Orn-Tyr(Bzl)-Pro-Gly]: a novel antiproliferative acting somatostatin receptor agonist with mu-opioid receptor-sensitizing properties.

Stirnweiss J, Hartrodt B, Greksch G, Stürzebecher U, Böhmer FD, Neubert K, Liebmann C.

Br J Pharmacol. 2003 Sep;140(1):13-22. Epub 2003 Aug 4.

18.

Intramolecular signal transduction by the bradykinin B2 receptor.

Mueller S, Liebmann C, Reissmann S.

Int Immunopharmacol. 2002 Dec;2(13-14):1763-70.

PMID:
12489790
19.
21.
22.
25.

Expression and functional characterization of a pHis-tagged human bradykinin B2 receptor in COS-7 cells.

Müller S, Adomeit A, Kaufmann R, Appelhans H, Passow H, Reissmann S, Liebmann C.

Biol Chem. 2000 Apr;381(4):343-7.

PMID:
10839464
29.

Bradykinin antagonists with dehydrophenylalanine analogues at position 5.

Greiner G, Dornberger U, Paegelow I, Schölkens BA, Liebmann C, Reissmann S.

J Pept Sci. 1998 Apr;4(2):92-100.

PMID:
9620613
30.

Novel bradykinin signalling events in PC-12 cells: stimulation of the cAMP pathway leads to cAMP-mediated translocation of protein kinase Cepsilon.

Graness A, Adomeit A, Ludwig B, Müller WD, Kaufmann R, Liebmann C.

Biochem J. 1997 Oct 1;327 ( Pt 1):147-54.

31.

Signaling effects of alpha-thrombin and SFLLRN in rat glioma C6 cells.

Kaufmann R, Lindschau C, Höer A, Henklein P, Adomeit A, Haller H, Liebmann C, Oberdisse E, Nowak G.

J Neurosci Res. 1996 Dec 15;46(6):641-51.

PMID:
8978498
32.

Tyrosine phosphorylation of GSalpha and inhibition of bradykinin-induced activation of the cyclic AMP pathway in A431 cells by epidermal growth factor receptor.

Liebmann C, Graness A, Boehmer A, Kovalenko M, Adomeit A, Steinmetzer T, Nürnberg B, Wetzker R, Boehmer FD.

J Biol Chem. 1996 Dec 6;271(49):31098-105.

33.

Highly selective bradykinin agonists and antagonists with replacement of proline residues by N-methyl-D- and L-phenylalanine.

Reissmann S, Schwuchow C, Seyfarth L, Pineda De Castro LF, Liebmann C, Paegelow I, Werner H, Stewart JM.

J Med Chem. 1996 Feb 16;39(4):929-36.

PMID:
8632416
34.

Dual bradykinin B2 receptor signalling in A431 human epidermoid carcinoma cells: activation of protein kinase C is counteracted by a GS-mediated stimulation of the cyclic AMP pathway.

Liebmann C, Graness A, Ludwig B, Adomeit A, Boehmer A, Boehmer FD, Nürnberg B, Wetzker R.

Biochem J. 1996 Jan 1;313 ( Pt 1):109-18.

35.

New cyclic bradykinin antagonists containing disulfide and lactam bridges at the N-terminal sequence.

Seyfarth L, Pineda de Castro LF, Liepina I, Paegelow I, Liebmann C, Reissmann S.

Int J Pept Protein Res. 1995 Aug;46(2):155-65.

PMID:
8567170
36.

The adenylate cyclase-inhibiting bradykinin receptor in guinea pig ileum membranes exhibits an unique antagonist profile.

Liebmann C, Graness A, Adomeit A, Nawrath S.

Eur J Pharmacol. 1995 Apr 28;289(2):403-7.

PMID:
7621918
37.

Potent photoaffinity labelled and iodinated antagonists of bradykinin.

Schumann C, Steinmetzer T, Gothe R, Hoppe A, Paegelow I, Liebmann C, Fabry M, Brandenburg D, Reissmann S.

Biol Chem Hoppe Seyler. 1995 Jan;376(1):33-8.

PMID:
7612186
38.

New photoaffinity labelled agonists of bradykinin.

Steinmetzer T, Schumann C, Paegelow I, Liebmann C, Glasmacher D, Brandenburg D, Reissmann S.

Biol Chem Hoppe Seyler. 1995 Jan;376(1):25-32.

PMID:
7612185
39.
41.

Affinity cross-linking of bradykinin B2 receptors in guinea pig ileum membranes.

Graness A, Liebmann C.

Eur J Pharmacol. 1994 Jul 15;268(2):271-4.

PMID:
7957650
42.

Pharmacological and molecular actions of the bradykinin B2 receptor antagonist, Hoe 140, in the rat uterus.

Liebmann C, Nawrath S, Ludwig B, Paegelow I.

Eur J Pharmacol. 1993 Apr 28;235(2-3):183-8.

PMID:
8389713
43.

Binding characteristics and functional G protein coupling of muscarinic acetylcholine receptors in rat duodenum smooth muscle membranes.

Liebmann C, Nawrath S, Schnittler M, Schubert H, Jakobs KH.

Naunyn Schmiedebergs Arch Pharmacol. 1992 Jan;345(1):7-15.

PMID:
1538792
44.

Structure-activity relationships of cyclic beta-casomorphin-5 analogues.

Schmidt R, Neubert K, Barth A, Liebmann C, Schnittler M, Chung NN, Schiller PW.

Peptides. 1991 Nov-Dec;12(6):1175-80.

PMID:
1667685
45.

Antagonist binding reveals two heterogenous B2 bradykinin receptors in rat myometrial membranes.

Liebmann C, Schnittler M, Stewart JM, Reissmann S.

Eur J Pharmacol. 1991 Jul 9;199(3):363-5.

PMID:
1655486
46.

High-affinity bradykinin receptor-catalyzed G protein activation in rat myometrium.

Liebmann C, Schnittler M, Nawrath S, Jakobs KH.

Eur J Pharmacol. 1991 May 25;207(1):67-71.

PMID:
1655496
47.

Structure-activity studies of novel casomorphin analogues: binding profiles towards mu 1-, mu 2- and delta -opioid receptors.

Liebmann C, Schnittler M, Hartrodt B, Born I, Neubert K.

Pharmazie. 1991 May;46(5):345-8.

PMID:
1654566
48.
49.

[Experimental design and interpretation of studies of radioligand binding].

Schnittler M, Liebmann C, Opfermann J.

Pharmazie. 1991 Jan;46(1):2-8. Review. German. No abstract available.

PMID:
1857726
50.

A high-affinity bradykinin receptor in membranes from rat myometrium is coupled to pertussis toxin-sensitive G-proteins of the Gi family.

Liebmann C, Offermanns S, Spicher K, Hinsch KD, Schnittler M, Morgat JL, Reissmann S, Schultz G, Rosenthal W.

Biochem Biophys Res Commun. 1990 Mar 30;167(3):910-7.

PMID:
2157433

Supplemental Content

Loading ...
Support Center